SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                 AMENDMENT NO 3
                                       TO
                                    FORM 10-K

              [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF

                       THE SECURITIES EXCHANGE ACT OF 1934

                   FOR THE FISCAL YEAR ENDED DECEMBER 31, 1999

                                       OR

          [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                             SECURITIES ACT OF 1934

          FOR THE TRANSITION PERIOD FROM _______________ TO ___________

                         COMMISSION FILE NUMBER 0-25406
                                                -------

                     TECHNICAL CHEMICALS AND PRODUCTS, INC.
             (Exact name of registrant as specified in its charter)

   Florida                                                65-0308922
   -------                                                ----------
   (State or jurisdiction of                          (I.R.S. Employer
   incorporation or organization)                    Identification No.)

   3341 S.W. 15th Street, Pompano Beach, Florida             33069
   ---------------------------------------------             -----
   (Address of principal executive offices)                (Zip Code)

       Registrant's telephone number, including area code: (954) 979-0400

           Securities Registered Pursuant to Section 12(b) of the Act:

                                                     Name of exchange
  Title of each class                                on which registered
  -------------------                                -------------------
  None                                               None

Securities registered pursuant to 12(g) of the Act: Common Stock, $.001 par
value

         Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding twelve months (or such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No ___

         Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [ ]

         The aggregate market value of Common Stock held by non-affiliates as of
March 27, 2000 was approximately $39,411,432 (based upon the closing sale price
of $1.59375 per share on the Nasdaq National Market on March 27, 2000).

         As of March 27, 2000, 29,541,258 shares of the Registrant's $.001 par
value Common Stock were outstanding.

                       Documents Incorporated By Reference
                       -----------------------------------
         The Registrant's Definitive Proxy Statement related to the 2000
        Annual Shareholder's Meeting is incorporated by reference in Part
          III to the extent provided in Items 10, 11, 12 and 13 hereof.


<PAGE>


<TABLE>
<CAPTION>

                           Technical Chemicals and Products, Inc. and Subsidiaries

                                       Consolidated Balance Sheets

                               (Amounts in thousands, except share data)

                                                                                              December 31
                                                                                        1999             1998
                                                                                      --------         --------
<S>                                                                                   <C>              <C>
Assets
Current assets:
   Cash and cash equivalents                                                          $  1,447         $  5,207
   Investments                                                                           2,540            5,048
   Accounts receivable, net                                                              1,163            1,605
   Inventory                                                                             2,036            2,550
   Due from related parties                                                                686              836
   Other                                                                                   486              210
                                                                                      --------         --------
Total current assets                                                                     8,358           15,456

Property and equipment, net                                                              2,096            2,503
Patents and trademarks, net                                                             11,256           12,190
Goodwill, net                                                                            1,807            1,979
Deferred tax asset, net                                                                      -            4,140
Other assets                                                                                71              101
                                                                                      --------         --------
Total assets                                                                          $ 23,588         $ 36,369
                                                                                      ========         ========


Liabilities and stockholders' equity
Current liabilities:
   Accounts payable                                                                   $    988        $     390
   Accrued expenses                                                                      1,360              323
                                                                                      --------        ---------
Total current liabilities                                                                2,348              713
Deferred revenue                                                                           812                -
Other liabilities                                                                            -              169
Stockholders' equity:
   Preferred stock, $.001 par value:
     authorized shares--25,000,000;
     11,350 and 14,700 shares of Series A 6%
       cumulative convertible issued and outstanding
       in 1999 and 1998, respectively                                                   12,457           13,131
   Common stock, $.001 par value:
     authorized shares--100,000,000;
     Issued and outstanding shares--14,541,544 in
       1999 and 10,006,316 in 1998                                                          15               10
   Additional paid-in capital                                                           41,638           40,697
   Accumulated deficit                                                                 (33,682)         (18,351)
                                                                                      --------        ---------
Total stockholders' equity                                                              20,428           35,487
                                                                                      --------        ---------
Total liabilities and stockholders' equity                                            $ 23,588        $  36,369
                                                                                      ========        =========
See accompanying notes.
</TABLE>



<PAGE>
<TABLE>
<CAPTION>

                              Technical Chemicals and Products, Inc. and Subsidiaries
                                       Consolidated Statements of Cash Flows

                                              (Amounts in Thousands)

                                                                             Year ended December 31
                                                                    1999             1998               1997
                                                              ------------------------------------------------------
<S>                                                                <C>               <C>               <C>
Operating activities
Net loss                                                           $(15,339)         $ (9,827)         $(4,489)
Adjustments to reconcile net loss to net cash used by
  operating activities:
     Income tax expense (benefit)                                     4,140                 -           (2,637)
     Depreciation                                                       476               484              399
     Amortization                                                     1,451             1,376            1,343
     Changes in operating assets and liabilities:
       Accounts receivable                                              442               450              123
       Inventory                                                        514              (698)            (812)
       Other current assets                                             (14)               16              264
       Change in other assets and liabilities                          (139)               (9)              (4)
       Accounts payable and accrued expenses                          1,635            (1,356)             409
       Deferred revenue                                                 812                 -                -
                                                              ------------------------------------------------------

Net cash used by operating activities                                (6,022)           (9,564)          (5,404)

Investing activities
Purchases of property and equipment                                    (328)             (344)            (697)
Due from related party                                                  150              (836)               -
Purchases of investments                                             (6,747)           (5,080)          (2,000)
Proceeds from sales of investments                                    9,263             3,988            9,626
Investment in patents and intangible assets                             (86)             (294)             (15)
                                                              ------------------------------------------------------
Net cash provided by (used in) investing activities                   2,252            (2,566)           6,914

Financing activities
Net proceeds from issuance of common stock                               10                 -                -
Net proceeds from issuance of preferred stock                             -            14,360                -
Proceeds from stock options or warrants exercised                         -                 -              199
Purchase of common stock                                                  -              (339)               -
                                                              ------------------------------------------------------
Net cash provided by financing activities                                10            14,021              199
                                                              ------------------------------------------------------
Net (decrease) increase in cash and cash equivalents                 (3,760)            1,891            1,709
Cash and cash equivalents at beginning of year                        5,207             3,316            1,607
                                                              ------------------------------------------------------
Cash and cash equivalents at end of year                          $   1,447          $  5,207          $ 3,316
                                                              ======================================================
Supplemental information
Cash paid during the year for interest                          $        15        $       16        $      14
                                                              ======================================================

Significant non-cash transactions
Issuance of warrants for future services                         $      262       $         -       $        -
                                                              ======================================================
</TABLE>

See accompanying notes.

<PAGE>

             Technical Chemicals and Products, Inc. and Subsidiaries
             Notes to Consolidated Financial Statements (Continued)


6. Income Taxes (continued)

The reconciliation of the expected income tax expense (benefit) with the actual
income tax expense (benefit) reported for the years ended December 31 computed
on loss before income taxes at federal statutory rates is as follows:
<TABLE>
<CAPTION>

                                                            1999             1998              1997
                                                     ------------------------------------------------------
<S>                                                       <C>               <C>              <C>
         Tax at federal statutory rate                    (34.0)%           (34.0)%          (34.0)%
         State and local income taxes, net of
            federal tax benefit                            (4.2)             (4.2)            (4.1)
         Nondeductible items                                 .5                .2               .1
         Change in valuation allowance                     74.3              38.4              -
         Other                                               .4               (.4)             1.0
                                                     ------------------------------------------------------
         Total                                             37.0%               - %           (37.0)%
                                                     ======================================================
</TABLE>

<PAGE>

             Technical Chemicals and Products, Inc. and Subsidiaries
             Notes to Consolidated Financial Statements (Continued)


10. Stockholders' Equity (continued)

For purposes of pro forma disclosures, the estimated fair value of the options
is amortized to expense over the options' vesting period. The Company's pro
forma information follows (amounts in thousands, except per share amounts):
<TABLE>
<CAPTION>

                                                            1999             1998              1997
                                                     ------------------------------------------------------

<S>                                                        <C>               <C>              <C>
         Pro forma net loss                                $(16,191)         $(10,606)        $(4,876)
         Accrued dividends on and accretion to
            redemption value of convertible
            preferred stock                                  (2,917)           (1,030)             -
                                                     ------------------------------------------------------
         Pro forma net loss attributable to common
            stockholders                                   $(19,108)         $(11,636)        $(4,876)
                                                     ======================================================
         Pro forma net loss per
            common share                                $    (1.72)       $    (1.16)       $    (.49)
                                                     ======================================================
</TABLE>


<PAGE>


                                   SIGNATURES

         Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.

                                     TECHNICAL CHEMICALS AND PRODUCTS, INC.


                                     By:    /s/ Walter V. Usinowicz, Jr.
                                           -----------------------------
                                           Walter V. Usinowicz, Jr.
                                           Vice President, Chief Financial
                                           Officer (Principal Financial Officer
                                           and Principal Accounting Officer)

                                           Date: June 8, 2000